-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on August 19 On August 17, the clinical application of Shandong Shengdi Pharmaceutical's Class 1 new drug HRS-8080 tablets was accepted by the CDE
.
According to data from Meinenet, from August 2021 to present, Hengrui Pharmaceuticals (including subsidiaries) has submitted 13 innovative drugs for clinical/marketing applications (including new indications, etc.
), of which 10 are Class 1 new drugs
.
.
According to data from Meinenet, from August 2021 to present, Hengrui Pharmaceuticals (including subsidiaries) has submitted 13 innovative drugs for clinical/marketing applications (including new indications, etc.
), of which 10 are Class 1 new drugs
.
Source: CDE official website
As the "first brother of innovative drugs", Hengrui Pharmaceuticals has always been a leader in R&D investment.
In 2021, R&D expenses were 1.
316 billion yuan, an increase of 62.
26% year-on-year; R&D expenses accounted for approximately 19% of revenue, an increase of 4.
3% year-on-year
.
In 2021, R&D expenses were 1.
316 billion yuan, an increase of 62.
26% year-on-year; R&D expenses accounted for approximately 19% of revenue, an increase of 4.
3% year-on-year
.
In the past 3 weeks (August 2021 until now), Hengrui Medicine has received CDE acceptance for the marketing/clinical application of 13 innovative drugs, including HRS-8080 tablets, SHR-A1921 for injection, HRS9531 injection, and SHR-A2009 for injection , HRS7415 tablets are the first clinical application
.
.
From August 2021 until now, Hengrui Medicine has applied for clinical new drugs
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Among the new drugs not declared for the first time, apatinib mesylate tablets and carrelizumab for injection have been approved for marketing; in addition, the highest research and development progress of many new drugs has entered phase III, and SHR8554 injection is A small molecule drug targeting the μ opioid receptor (MOR), the indication for postoperative pain is undergoing phase II/III clinical trials; SHR0410 injection is a selective kappa opioid receptor agonist, adapted for postoperative pain Phase III clinical trials are in progress; Famitinib Malate Capsules is a small molecule multi-target tyrosine kinase inhibitor, and advanced gastrointestinal stromal tumors and other indications are undergoing Phase III clinical trials; SHR-1701 injection is A bispecific antibody targeting PD-L1 and TGFβ, the indication for advanced colorectal cancer is undergoing phase II/III clinical trials
.
.
In terms of indications, anti-tumor drugs are the main therapeutic area of Hengrui Medicine
.
Meters within the network data show that in 2020 China's urban public hospitals , county-level public hospitals, urban community centers and township hospitals (referred to as the Chinese public medical institutions) and Chinese cities entity pharmacy terminal anti -tumor drug market size of over 100 billion yuan
.
.
Meters within the network data show that in 2020 China's urban public hospitals , county-level public hospitals, urban community centers and township hospitals (referred to as the Chinese public medical institutions) and Chinese cities entity pharmacy terminal anti -tumor drug market size of over 100 billion yuan
.
Sales of terminal anti-tumor drugs in physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
For newly approved innovative drugs, retail pharmacies are the main battlefield for sales
.
Thanks to the increase in the number of new drugs approved and the efforts of DTP pharmacies and other out-of-hospital markets, the size of the terminal antineoplastic drug market in China's urban physical pharmacies has increased year by year.
The growth rate in 2020 will exceed 30%, which is higher than the growth rate of China's public medical institutions (9.
6 %)
.
.
Thanks to the increase in the number of new drugs approved and the efforts of DTP pharmacies and other out-of-hospital markets, the size of the terminal antineoplastic drug market in China's urban physical pharmacies has increased year by year.
The growth rate in 2020 will exceed 30%, which is higher than the growth rate of China's public medical institutions (9.
6 %)
.
Source: Mi Nei.
com database, CDE official website, etc.
com database, CDE official website, etc.
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of August 18th, if there are any omissions, please correct me!
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of August 18th, if there are any omissions, please correct me!
Medical Network News on August 19 On August 17, the clinical application of Shandong Shengdi Pharmaceutical's Class 1 new drug HRS-8080 tablets was accepted by the CDE
.
According to data from Meinenet, from August 2021 to present, Hengrui Pharmaceuticals (including subsidiaries) has submitted 13 innovative drugs for clinical/marketing applications (including new indications, etc.
), of which 10 are Class 1 new drugs
.
.
According to data from Meinenet, from August 2021 to present, Hengrui Pharmaceuticals (including subsidiaries) has submitted 13 innovative drugs for clinical/marketing applications (including new indications, etc.
), of which 10 are Class 1 new drugs
.
Source: CDE official website
As the "first brother of innovative drugs", Hengrui Pharmaceuticals has always been a leader in R&D investment.
In 2021, R&D expenses were 1.
316 billion yuan, an increase of 62.
26% year-on-year; R&D expenses accounted for approximately 19% of revenue, an increase of 4.
3% year-on-year
.
In 2021, R&D expenses were 1.
316 billion yuan, an increase of 62.
26% year-on-year; R&D expenses accounted for approximately 19% of revenue, an increase of 4.
3% year-on-year
.
In the past 3 weeks (August 2021 until now), Hengrui Medicine has received CDE acceptance for the marketing/clinical application of 13 innovative drugs, including HRS-8080 tablets, SHR-A1921 for injection, HRS9531 injection, and SHR-A2009 for injection , HRS7415 tablets are the first clinical application
.
.
From August 2021 until now, Hengrui Medicine has applied for clinical new drugs
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Among the new drugs not declared for the first time, apatinib mesylate tablets and carrelizumab for injection have been approved for marketing; in addition, the highest research and development progress of many new drugs has entered phase III, and SHR8554 injection is A small molecule drug targeting the μ opioid receptor (MOR), the indication for postoperative pain is undergoing phase II/III clinical trials; SHR0410 injection is a selective kappa opioid receptor agonist, adapted for postoperative pain Phase III clinical trials are in progress; Famitinib Malate Capsules is a small molecule multi-target tyrosine kinase inhibitor, and advanced gastrointestinal stromal tumors and other indications are undergoing Phase III clinical trials; SHR-1701 injection is A bispecific antibody targeting PD-L1 and TGFβ, the indication for advanced colorectal cancer is undergoing phase II/III clinical trials
.
.
In terms of indications, anti-tumor drugs are the main therapeutic area of Hengrui Medicine
.
Meters within the network data show that in 2020 China's urban public hospitals , county-level public hospitals, urban community centers and township hospitals (referred to as the Chinese public medical institutions) and Chinese cities entity pharmacy terminal anti -tumor drug market size of over 100 billion yuan
.
.
Meters within the network data show that in 2020 China's urban public hospitals , county-level public hospitals, urban community centers and township hospitals (referred to as the Chinese public medical institutions) and Chinese cities entity pharmacy terminal anti -tumor drug market size of over 100 billion yuan
.
Sales of terminal anti-tumor drugs in physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
For newly approved innovative drugs, retail pharmacies are the main battlefield for sales
.
Thanks to the increase in the number of new drugs approved and the efforts of DTP pharmacies and other out-of-hospital markets, the size of the terminal antineoplastic drug market in China's urban physical pharmacies has increased year by year.
The growth rate in 2020 will exceed 30%, which is higher than the growth rate of China's public medical institutions (9.
6 %)
.
.
Thanks to the increase in the number of new drugs approved and the efforts of DTP pharmacies and other out-of-hospital markets, the size of the terminal antineoplastic drug market in China's urban physical pharmacies has increased year by year.
The growth rate in 2020 will exceed 30%, which is higher than the growth rate of China's public medical institutions (9.
6 %)
.
Source: Mi Nei.
com database, CDE official website, etc.
com database, CDE official website, etc.
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of August 18th, if there are any omissions, please correct me!
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of August 18th, if there are any omissions, please correct me!
Medical Network News on August 19 On August 17, the clinical application of Shandong Shengdi Pharmaceutical's Class 1 new drug HRS-8080 tablets was accepted by the CDE
.
According to data from Meinenet, from August 2021 to present, Hengrui Pharmaceuticals (including subsidiaries) has submitted 13 innovative drugs for clinical/marketing applications (including new indications, etc.
), of which 10 are Class 1 new drugs
.
.
According to data from Meinenet, from August 2021 to present, Hengrui Pharmaceuticals (including subsidiaries) has submitted 13 innovative drugs for clinical/marketing applications (including new indications, etc.
), of which 10 are Class 1 new drugs
.
Source: CDE official website
As the "first brother of innovative drugs", Hengrui Pharmaceuticals has always been a leader in R&D investment.
In 2021, R&D expenses were 1.
316 billion yuan, an increase of 62.
26% year-on-year; R&D expenses accounted for approximately 19% of revenue, an increase of 4.
3% year-on-year
.
Medicine Medicine MedicineIn 2021, R&D expenses were 1.
316 billion yuan, an increase of 62.
26% year-on-year; R&D expenses accounted for approximately 19% of revenue, an increase of 4.
3% year-on-year
.
In the past 3 weeks (August 2021 until now), Hengrui Medicine has received CDE acceptance for the marketing/clinical application of 13 innovative drugs, including HRS-8080 tablets, SHR-A1921 for injection, HRS9531 injection, and SHR-A2009 for injection , HRS7415 tablets are the first clinical application
.
.
From August 2021 until now, Hengrui Medicine has applied for clinical new drugs
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Among the new drugs not declared for the first time, apatinib mesylate tablets and carrelizumab for injection have been approved for marketing; in addition, the highest research and development progress of many new drugs has entered phase III, and SHR8554 injection is A small molecule drug targeting the μ opioid receptor (MOR), the indication for postoperative pain is undergoing phase II/III clinical trials; SHR0410 injection is a selective kappa opioid receptor agonist, adapted for postoperative pain Phase III clinical trials are in progress; Famitinib Malate Capsules is a small molecule multi-target tyrosine kinase inhibitor, and advanced gastrointestinal stromal tumors and other indications are undergoing Phase III clinical trials; SHR-1701 injection is A bispecific antibody targeting PD-L1 and TGFβ, the indication for advanced colorectal cancer is undergoing phase II/III clinical trials
.
.
In terms of indications, anti-tumor drugs are the main therapeutic area of Hengrui Medicine
.
Meters within the network data show that in 2020 China's urban public hospitals , county-level public hospitals, urban community centers and township hospitals (referred to as the Chinese public medical institutions) and Chinese cities entity pharmacy terminal anti -tumor drug market size of over 100 billion yuan
.
Hospital hospital hospital pharmacy pharmacy pharmacy tumor tumor tumor.
Meters within the network data show that in 2020 China's urban public hospitals , county-level public hospitals, urban community centers and township hospitals (referred to as the Chinese public medical institutions) and Chinese cities entity pharmacy terminal anti -tumor drug market size of over 100 billion yuan
.
Sales of terminal anti-tumor drugs in physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
For newly approved innovative drugs, retail pharmacies are the main battlefield for sales
.
Thanks to the increase in the number of new drugs approved and the efforts of DTP pharmacies and other out-of-hospital markets, the size of the terminal antineoplastic drug market in China's urban physical pharmacies has increased year by year.
The growth rate in 2020 will exceed 30%, which is higher than the growth rate of China's public medical institutions (9.
6 %)
.
.
Thanks to the increase in the number of new drugs approved and the efforts of DTP pharmacies and other out-of-hospital markets, the size of the terminal antineoplastic drug market in China's urban physical pharmacies has increased year by year.
The growth rate in 2020 will exceed 30%, which is higher than the growth rate of China's public medical institutions (9.
6 %)
.
Source: Mi Nei.
com database, CDE official website, etc.
com database, CDE official website, etc.
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of August 18th, if there are any omissions, please correct me!
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of August 18th, if there are any omissions, please correct me!
